23720 Federal Register / Vol. 66, No. 90 / Wednesday, May 9, 2001 / Notices

committee trade secret and/or

confidential commercial information (5

U.S.C. 552b(c)(4)) regarding pending

and future device issues. In addition,

the committee will discuss and review

trade secret and/or confidential

commercial information presented by a

sponsor.

FDA regrets that it was unable to

publish this notice 15 days prior to the

May 21 and 22, 2001, Obstetrics and

Gynecology Devices Panel of the

Medical Devices Advisory Committee

meeting. Because the agency believes

there is some urgency to bring these

issues to public discussion and

qualified members of the Obstetrics and

Gynecology Devices Panel of the

Medical Devices Advisory Committee

were available at this time, the

Commissioner of Food and Drugs

concluded that it was in the public

interest to hold this meeting even if

there was not sufficient time for the

customary 15-day public notice.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: May 4, 2001.

Bonnie Malkin,

Special Assistant to the Senior Associate

Commissioner.

[FR Doc. 01–11732 Filed 5–4–01; 4:54 pm]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended

Notice of Meeting

Notice is hereby given of a change in

the meeting of the Advisory Committee

to the Director, National Cancer

Institute, May 10, 2001, 12 pm to May

10, 2001, 1 pm, National Cancer

Institute, National Institutes of Health,

9000 Rockville Pike, Building 31, Room

11A03, Bethesda, MD 20892 which was

published in the Federal Register on

April 19, 2001, 66 FR 20152.

The meeting will be held on

Thursday, May 24, 2001. The meeting is

open to the public.

Dated: May 1, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–11595 Filed 5–8–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended

Notice of Meeting

Notice is hereby given of a change in

the meeting of the National Cancer

Institute Special Emphasis Panel, April

30, 2001, 8 a.m. to May 1, 2001, 5 p.m.,

Ramada Inn Rockville, 1775 Rockville

Pike, Rockville, MD 20852 which was

published in the Federal Register on

April 19, 2001, 66 FR 20151.

The meeting will be held on

Thursday, May 24 and Friday, May 25,

2001. The meeting is closed to the

public.

Dated: May 1, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–11599 Filed 5–8–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute, Special Emphasis Panel, Molecular

Pathways of Bladder Cancer Progression.

Date: May 23, 2001.

Time: 12 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant

applications and/or proposals.

Place: National Cancer Institute, Grants

Review Branch, Division of Extramural

Activities, 6116 Executive Boulevard, Room

8127, Bethesda, MD 20892 (Telephone

Conference Call).

Contact Person: Michael B. Small, Ph.D,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8127, Bethesda, MD 20892,

301/402–0996.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: May 1, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–11600 Filed 5–8–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the meeting of the

National Cancer Advisory Board.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

A portion of the meeting will be

closed to the public in accordance with

the provisions set forth in sections

552b(c)(4), and 552b(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Advisory.

Date: May 22, 2001.

Open: 8:45 a.m. to 12 p.m..

Agenda: Program reports and

presentations; Business of the board.